GRAL Shareholder Alert: Grail, Inc. Faces Class Action Lawsuit After Trial Results Fail to Meet Expectations
GRAL Shareholder Alert: Grail, Inc. Faces Class Action Lawsuit
In a recent and alarming announcement, Grail, Inc. (NASDAQ: GRAL) has found itself embroiled in a class action lawsuit following the disappointing results of its NHS-Galleri trial. The study, which involved over 140,000 participants, was designed to deliver a statistically significant decrease in Stage III and IV cancers. However, on February 19, 2026, the company revealed that this primary endpoint was not achieved, leading to a staggering 50.55% plummet in its stock price in just one day.
Understanding the NHS-Galleri Trial
The NHS-Galleri trial was touted by Grail as a groundbreaking study that would significantly alter cancer screening methods. During the class period spanning from May 13, 2025, to February 19, 2026, Grail's management continuously asserted that the trial was on a promising trajectory. They noted, for instance, that the positive predictive value (PPV) was
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.